Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and treating Systemic Lupus Erythematosis

摘要

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.